Taurine (Longevity).

Cysteine is the sulfur source for taurine through cysteine dioxygenase and cysteine sulfinate decarboxylase. Circulating taurine falls when cysteine flux is limited, so the pair is a precursor with its product.

NAC delivers cysteine that the body splits between glutathione synthesis and the taurine branch, so the two routes draw on one pool. Supplying taurine directly leaves more NAC-derived cysteine for glutathione instead of the sulfur oxidation branch.

Glutathione and taurine are two major endpoints of cysteine metabolism and neither converts into the other. Covering both means the sulfur pathway is supported at both ends rather than one branch being fed at the other's expense.

The decarboxylation of cysteine sulfinate to hypotaurine depends on pyridoxal-5-phosphate. Endogenous taurine output tracks B6 status.

Both act to restrain calcium entry and stabilise excitable membranes, magnesium at the channel and taurine as an intracellular counter-ion. Magnesium taurate exists as a single salt for that reason.

Taurine, betaine and myo-inositol are the main compatible organic osmolytes cells accumulate to hold volume without disturbing protein function, and cells substitute one for another. Supplying more than one reduces the load on any single transporter.

Myo-inositol sits alongside taurine as a cellular osmolyte, and tissue content of the two shifts reciprocally as osmotic conditions change. They cover the same job through separate transporters.

Glycine and taurine are both small amino acids that act at the inhibitory glycine receptor and serve as osmolytes. Their membrane effects overlap through a single settled mechanism.

Beta-alanine competes with taurine for the TauT transporter, so a heavy beta-alanine load lowers tissue taurine accumulation. It is the clearest honest anti-synergy for any taurine product.

Methionine is adenosylated to S-adenosylmethionine, demethylated to homocysteine, then condensed with serine by cystathionine beta-synthase and cleaved to cysteine. Cysteine is oxidised by cysteine dioxygenase and decarboxylated to hypotaurine, which is oxidised to taurine. Methionine therefore sits two steps upstream of endogenous taurine. This is textbook sulfur amino acid metabolism.

TauT, encoded by SLC6A6, moves taurine into the cell against its concentration gradient by coupling to the inward movement of two sodium ions and one chloride ion. The energy comes from the sodium gradient maintained by the sodium-potassium ATPase. Taurine transport therefore depends on sodium handling rather than on taurine concentration alone. This is established membrane transport physiology.

When a cell swells it loses potassium, chloride and organic osmolytes including taurine through volume-regulated anion channels, shrinking back toward its set point. Taurine is one of the largest organic osmolyte pools in heart, brain and muscle. Its handling is therefore tied to the same volume regulation that governs potassium. The mechanism is settled cell physiology.

Bile acid-CoA:amino acid N-acyltransferase conjugates cholic and chenodeoxycholic acid with either taurine or glycine, which lowers the pKa and keeps the bile salt ionised and micelle-forming at intestinal pH. Taurine conjugates are more water soluble across a wider pH range than glycine conjugates. Taurine supply is one determinant of the taurine to glycine conjugation ratio. This is established hepatic biochemistry.

Cysteine sulfinic acid decarboxylase converts cysteine sulfinate to hypotaurine and requires pyridoxal 5-phosphate at its active site. Cystathionine beta-synthase and cystathionine gamma-lyase, the two transsulfuration enzymes that make cysteine available, are also pyridoxal 5-phosphate dependent. Vitamin B6 status therefore governs how much taurine the body can make. This is settled cofactor biochemistry.

Cysteine catabolism splits between the cysteine dioxygenase route that ends in taurine and the desulfhydration route that ends in sulfate by way of sulfite oxidase, a molybdenum cofactor enzyme. Which way the flux goes determines how much sulfur ends up as taurine and how much as inorganic sulfate. Molybdenum status is one input to that split. The enzymology is established.

Taurine is structurally close to gamma-aminobutyric acid and behaves as a weak agonist at GABA-A receptors and at strychnine-sensitive glycine receptors in preclinical preparations. That overlap is well characterised in animal and cell work. Whether it translates into a measurable effect from oral taurine in people is much less clear. Read it as receptor pharmacology, not as a clinical claim.

Taurine is required for the taurinomethyluridine modification of mitochondrial transfer RNA, which supports translation of mitochondrially encoded respiratory chain subunits. Coenzyme Q10 carries electrons between complexes I and II and complex III of that same chain. The two therefore touch mitochondrial respiration at different points. The combination has not been measured together, so this is a mechanistic overlap rather than a tested pairing.

Carnitine shuttles long-chain fatty acyl groups across the inner mitochondrial membrane for beta-oxidation. Taurine supports mitochondrial translation and acts as an intracellular osmolyte in the same tissues. Their roles are distinct and neither depends on the other. The pairing rests on shared tissue distribution and formulation practice.

Taurine appears alongside caffeine in almost all energy drink formulations, which is why much of the human data on taurine comes from mixtures where caffeine is present. That makes the taurine contribution hard to isolate from those studies. The pairing is a formulation fact worth stating plainly. It is not evidence that taurine adds to what caffeine does.

Alpha-lipoic acid cycles between dithiol and disulfide forms and is the covalently bound cofactor for the pyruvate and alpha-ketoglutarate dehydrogenase complexes. Taurine's redox contribution runs through taurine chloramine formation in neutrophils and through its osmolyte and membrane-stabilising roles. The two are chemically distinct sulfur compounds with different jobs. The pairing is convention, not a demonstrated interaction.

Taurine forms coordination complexes with zinc, and zinc taurate is used as a mineral salt in its own right. Both are concentrated in retinal tissue. The pairing has a chemical basis in the salt and a formulation basis in their shared tissue distribution. It has not been tested as a combination for an outcome.

Retinal tissue holds taurine at very high intracellular concentration, and the loss of dietary taurine causes photoreceptor degeneration in cats, which is where the requirement was first established. Lutein concentrates in the macula as a xanthophyll pigment. The two occupy the same tissue by different routes. The combination is a formulation convention supported by tissue distribution rather than by a trial.

Spermidine is a polyamine studied in relation to autophagy, and taurine appears in the same body of ageing-related metabolite work. No shared enzymatic step connects them. The row records why they are formulated together and labels the basis as convention. Nothing measured supports the combination.

Nicotinamide mononucleotide feeds the nicotinamide adenine dinucleotide salvage pathway, a route that has no overlap with sulfur amino acid metabolism. The two are combined because they occupy the same product category. This row exists to record that convention honestly. It is not a mechanistic pairing.

Urolithin A is a gut microbial metabolite of ellagitannins studied for its effect on mitophagy. Taurine supports mitochondrial transfer RNA modification. Both touch mitochondria, by unrelated routes and at different levels of evidence. The pairing is category convention and is labelled as such.